SEARCH

SEARCH BY CITATION

REFERENCES

  • Agalioti T, Chen G, Thanos D. 2002. Deciphering the transcriptional histone acetylation code for a human gene. Cell 111: 381392.
  • Alarcon-Vargas D, Zhang Z, Agarwal B, Challagulla K, Mani S, Kalpana GV. 2006. Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene 25: 722734.
  • Albini S, Puri PL. 2010. SWI/SNF complexes, chromatin remodeling and skeletal myogenesis: It's time to exchange! Exp Cell Res 316: 30733080.
  • Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J. 2000. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54: 7176.
  • Ariumi Y, Serhan F, Turelli P, Telenti A, Trono D. 2006. The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription. Retrovirology 3: 47.
  • Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, Vivarelli R, Genuardi M, Papi L. 2010. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics 11: 7380.
  • Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS. 2005. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res 65: 35423547.
  • Bannwarth S, Gatignol A. 2005. HIV-1 TAR RNA: The target of molecular interactions between the virus and its host. Curr HIV Res 3: 6171.
  • Baser ME, Friedman JM, Evans DG. 2006. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 66: 730732.
  • Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. 2002. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 21: 51935203.
  • Bourdeaut F, Lequin D, Brugieres L, Reynaud S, Dufour C, Doz F, Andre N, Stephan JL, Perel Y, Oberlin O, Orbach D, Bergeron C, Rialland X, Freneaux P, Ranchere D, Figarella-Branger D, Audry G, Puget S, Evans DG, Pinas JC, Capra V, Mosseri V, Coupier I, Gauthier-Villars M, Pierron G, Delattre O. 2011. Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor. Clin Cancer Res 17: 3138.
  • Boyd C, Smith MJ, Kluwe L, Balogh A, MacCollin M, Plotkin SR. 2008. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 74: 358366.
  • Bruder CE, Dumanski JP, Kedra D. 1999. The mouse ortholog of the human SMARCB1 gene encodes two splice forms. Biochem Biophys Res Commun 257: 886890.
  • Bultman SJ, Herschkowitz JI, Godfrey V, Gebuhr TC, Yaniv M, Perou CM, Magnuson T. 2008. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27: 460468.
  • Cairns BR. 1998. Chromatin remodeling machines: Similar motors, ulterior motives. Trends Biochem Sci 23: 2025.
  • Cairns BR. 2007. Chromatin remodeling: Insights and intrigue from single-molecule studies. Nat Struct Mol Biol 14: 989996.
  • Caramel J, Medjkane S, Quignon F, Delattre O. 2008. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Oncogene 27: 20352044.
  • Carter JM, O'Hara C, Dundas G, Gilchrist D, Collins MS, Eaton K, Judkins AR, Biegel JA, Folpe AL. 2012. Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with “neuroblastoma-like” schwannomatosis and a novel germline SMARCB1 mutation. Am J Surg Pathol 36: 154160.
  • Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV. 1999. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22: 102105.
  • Christiaans I, Kenter SB, Brink HC, van Os TA, Bass F, van den Munckhof P, Kidd AM, Hulsebos TJ. 2011. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet 2011: 9397.
  • Clerzius G, Gelinas JF, Gatignol A. 2011. Multiple levels of PKR inhibition during HIV-1 replication. Rev Med Virol 21: 4253.
  • Corbeau P. 2008. Interfering RNA and HIV: Reciprocal interferences. PLoS Pathog 4: e1000162.
  • Craig E, Zhang ZK, Davies KP, Kalpana GV. 2002. A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: Implications for tumorigenesis. EMBO J 21: 3142.
  • Cui K, Tailor P, Liu H, Chen X, Ozato K, Zhao K. 2004. The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming. Mol Cell Biol 24: 44764486.
  • Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. 2010. Aurora kinase inhibitors–rising stars in cancer therapeutics? Mol Cancer Ther 9: 268278.
  • Datta J, Majumder S, Bai S, Ghoshal K, Kutay H, Smith DS, Crabb JW, Jacob ST. 2005. Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells. Cancer Res 65: 1089110900.
  • DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V. 2007. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4: 5757.
  • Doerflinger NH, Macklin WB, Popko B. 2003. Inducible site-specific recombination in myelinating cells. Genesis 35: 6372.
  • Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA. 2011a. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 56: 715.
  • Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA. 2011b. Spectrum of SMARCB1/INI1 Mutations in Familial and Sporadic Rhabdoid Tumors. Pediatr Blood Cancer 56: 715.
  • Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. 2006. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour prone syndromes. J Med Genet 43: 289294.
  • Evans DG, Mason S, Huson SM, Ponder M, Harding AE, Strachan T. 1997. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: A clinical and molecular study. J Neurol Neurosurg Psychiatry 62: 361366.
  • Foster KS, McCrary WJ, Ross JS, Wright CF. 2006. Members of the hSWI/SNF chromatin remodeling complex associate with and are phosphorylated by protein kinase B/Akt. Oncogene 25: 46054612.
  • Gerszten PC, Quader M, Novotny J, Flickinger JC. 2012. Radiosurgery for benign tumors of the spine: Clinical experience and current trends. Technol Cancer Res Treat 11: 133139.
  • Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, van der Valk M, Woodruff JM, Goutebroze L, Merel P, Berns A, Thomas G. 1999. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 13: 978986.
  • Gonzalvo A, Fowler A, Cook RJ, Little NS, Wheeler H, McDonald KL, Biggs MT. 2011. Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: A surgical series with long-term follow-up. J Neurosurg 114: 756762.
  • Gresh L, Bourachot B, Reimann A, Guigas B, Fiette L, Garbay S, Muchardt C, Hue L, Pontoglio M, Yaniv M, Klochendler-Yeivin A. 2005. The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation. EMBO J 24: 33133324.
  • Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W, Smith TW, Imbalzano AN, Jones SN. 2001. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 21: 35983603.
  • Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG. 2008. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 45: 332339.
  • Hadfield KD, Smith MJ, Trump D, Newman WG, Evans DG. 2010a. SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet 47: 568.
  • Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT, Rutherford SA, Trump D, Newman WG, Evans DG. 2010b. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29: 62166221.
  • Harder A, Wesemann M, Hagel C, Schittenhelm J, Fischer S, Tatagiba M, Nagel C, Jeibmann A, Bohring A, Mautner VF, Paulus W. 2012. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol 36: 702709.
  • Hulsebos TJ, Kenter SB, Jakobs ME, Baas F, Chong B, Delatycki MB. 2010. SMARCB1/INI1 maternal germ line mosaicism in schwannomatosis. Clin Genet 77: 8691.
  • Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P. 2007. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80: 805810.
  • Jacoby LB, Jones D, Davis K, Kronn D, Short MP, Gusella J, MacCollin M. 1997. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 61: 12931302.
  • Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CW, Dorsch M. 2010. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 16: 14291433.
  • Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP. 1994. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 266: 20022006.
  • Kalpana GV, Smith ME. 2010. Development of targeted therapies for rhabdoid tumors based on the functions of INI1/hSNF5 tumor suppressor. In: Peter J. Houghton, Robert J. Arceci, editors. Molecularly targeted therapy for childhood cancer. New York: Springer. pp. 305330.
  • Kaufman DL, Heinrich BS, Willett C, Perry A, Finseth F, Sobel RA, MacCollin M. 2003. Somatic instability of the NF2 gene in schwannomatosis. Arch Neurol 60: 13171320.
  • Kim JK, Huh SO, Choi H, Lee KS, Shin D, Lee C, Nam JS, Kim H, Chung H, Lee HW, Park SD, Seong RH. 2001. Srg3, a mouse homolog of yeast SWI3, is essential for early embryogenesis and involved in brain development. Mol Cell Biol 21: 77877795.
  • Kingston RE, Narlikar GJ. 1999. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev 13: 23392352.
  • Kitzen JJ, de Jonge MJ, Verweij J. 2010. Aurora kinase inhibitors. Crit Rev Oncol Hematol 73: 99110.
  • Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M. 2000. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 1: 500506.
  • Krosl J, Mamo A, Chagraoui J, Wilhelm BT, Girard S, Louis I, Lessard J, Perreault C, Sauvageau G. 2010. A mutant allele of the Swi/Snf member BAF250a determines the pool size of fetal liver hemopoietic stem cell populations. Blood 116: 16781684.
  • Lee D, Sohn H, Kalpana GV, Choe J. 1999. Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA. Nature 399: 487491.
  • Lee JY, Kim H, Ryu CH, Kim JY, Choi BH, Lim Y, Huh PW, Kim YH, Lee KH, Jun TY, Rha HK, Kang JK, Choi CR. 2004. Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. J Biol Chem 279: 3026530273.
  • Lee S, Cimica V, Ramachandra N, Zagzag D, Kalpana GV. 2011. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. Cancer Res 71: 32253235.
  • Lesbats P, Botbol Y, Chevereau G, Vaillant C, Calmels C, Arneodo A, Andreola ML, Lavigne M, Parissi V. 2011. Functional coupling between HIV-1 integrase and the SWI/SNF chromatin remodeling complex for efficient in vitro integration into stable nucleosomes. PLoS Pathog 7: e1001280.
  • Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM, Staahl BT, Wu H, Aebersold R, Graef IA, Crabtree GR. 2007. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron 55: 201215.
  • Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG. 2010. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140: 477490.
  • Liu H, Kang H, Liu R, Chen X, Zhao K. 2002. Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. Mol Cell Biol 22: 64716479.
  • MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. 2005. Diagnostic criteria for schwannomatosis. Neurology 64: 18381845.
  • MacCollin M, Willett C, Heinrich B, Jacoby LB, Acierno JS Jr, Perry A, Louis DN. 2003. Familial schwannomatosis: Exclusion of the NF2 locus as the germline event. Neurology 60: 19681974.
  • MacCollin M, Woodfin W, Kronn D, Short MP. 1996. Schwannomatosis: A clinical and pathologic study. Neurology 46: 10721079.
  • Mahmoudi T, Parra M, Vries RG, Kauder SE, Verrijzer CP, Ott M, Verdin E. 2006. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Bio Chem 281: 1996019968.
  • Martens JA, Winston F. 2003. Recent advances in understanding chromatin remodeling by Swi/Snf complexes. Curr Opin Genet Dev 13: 136142.
  • Matsumoto S, Banine F, Struve J, Xing R, Adams C, Liu Y, Metzger D, Chambon P, Rao MS, Sherman LS. 2006. Brg1 is required for murine neural stem cell maintenance and gliogenesis. Dev Biol 289: 372383.
  • Medjkane S, Novikov E, Versteege I, Delattre O. 2004. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization. Cancer Res 64: 34063413.
  • Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. 2012. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist 17: 13171322.
  • Messing A, Behringer RR, Hammang JP, Palmiter RD, Brinster RL, Lemke G. 1992. P0 promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice. Neuron 8: 507520.
  • Messing A, Behringer RR, Wrabetz L, Hammang JP, Lemke G, Palmiter RD, Brinster RL. 1994. Hypomyelinating peripheral neuropathies and schwannomas in transgenic mice expressing SV40 T-antigen. J Neurosci 14: 35333539.
  • Morozov A, Lee SJ, Zhang ZK, Cimica V, Zagzag D, Kalpana GV. 2007. INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors. Clin Cancer Res 13: 47214730.
  • Morozov A, Yung E, Kalpana G. 1998. Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region. Proc Natl Acad Sci USA 95: 11201125.
  • Murray A, Hughes TAT, Neal JW, Howard E, Evans DGR, Harper PS. 2006. A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2? J Neurol Neurosurg Psychiatry 77: 269271.
  • Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. 2008. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 14: 44554462.
  • Narlikar GJ, Fan HY, Kingston RE. 2002. Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475487.
  • Niranjan A, Mathieu D, Flickinger JC, Kondziolka D, Lunsford LD. 2008. Hearing preservation after intracanalicular vestibular schwannoma radiosurgery. Neurosurgery 63: 10541062.
  • Nowak SJ, Aihara H, Gonzalez K, Nibu Y, Baylies MK. 2012. Akirin links twist-regulated transcription with the Brahma chromatin remodeling complex during embryogenesis. PLoS Genet 8: e1002547.
  • Osley MA, Tsukuda T, Nickoloff JA. 2007. ATP-dependent chromatin remodeling factors and DNA damage repair. Mutat Res 618: 6580.
  • Patil S, Perry A, MacCollin M, Dong S, Betensky RA, Yeh TH, Gutmann DH, Stemmer-Rachamimov AO. 2008. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol 18: 517519.
  • Pattenden SG, Klose R, Karaskov E, Bremner R. 2002. Interferon-gamma-induced chromatin remodeling at the CIITA locus is BRG1 dependent. EMBO J 21: 19781986.
  • Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. 2012. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 7: e35711.
  • Pollard JR, Mortimore M. 2009. Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 52: 26292651.
  • Racki LR, Narlikar GJ. 2008. ATP-dependent chromatin remodeling enzymes: Two heads are not better, just different. Curr Opin Genet Dev 18: 137144.
  • Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M. 1998. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J 17: 69796991.
  • Rieske P, Zakrzewska M, Piaskowski S, Jaskolski D, Sikorska B, Papierz W, Zakrzewski K, Liberski PP. 2003. Molecular heterogeneity of meningioma with INI1 mutation. Mol Pathol 56: 299301.
  • Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. 2000. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 97: 1379613800.
  • Roberts CW, Leroux MM, Fleming MD, Orkin SH. 2002. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2: 415425.
  • Rousseau G, Noguchi T, Bourdon V, Sobol H, Olschwang S. 2011. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. BMC Neurol 11: 99.
  • Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E. 1998. The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci U S A 95: 41524157.
  • Schmitz U, Mueller W, Weber M, Sevenet N, Delattre O, von Deimling A. 2001. INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 84: 199201.
  • Seo S, Richardson GA, Kroll KL. 2005. The SWI/SNF chromatin remodeling protein Brg1 is required for vertebrate neurogenesis and mediates transactivation of Ngn and NeuroD. Development 132: 105115.
  • Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L. 2008. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat 29: 227231.
  • Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV. 2008. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 14: 523532.
  • Smith ME, Cimica V, Chinni S, Jana S, Koba W, Yang Z, Fine E, Zagzag D, Montagna C, Kalpana GV. 2011. Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1. Proc Natl Acad Sci USA 108: 319324.
  • Smith MJ, Wallace AJ, Bowers NL, Rustad CF, Woods CG, Leschziner GD, Ferner RE, Evans DG. 2012. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics 13: 141145.
  • Sorin M, Kalpana GV. 2006. Dynamics of virus-host interplay in HIV-1 replication. Curr HIV Res 4: 117130.
  • Swensen JJ, Keyser J, Coffin CM, Biegel JA, Viskochil DH, Williams MS. 2009. Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1. J Med Genet 46: 6872.
  • Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV. 2005. Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci USA 102: 1212912134.
  • van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJ. 2012. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 13: 17.
  • van Vugt JJ, Ranes M, Campsteijn C, Logie C. 2007. The ins and outs of ATP-dependent chromatin remodeling in budding yeast: Biophysical and proteomic perspectives. Biochim Biophys Acta 1769: 153171.
  • Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O. 1998. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203206.
  • Vries RG, Bezrookove V, Zuiderduijn LM, Kia SK, Houweling A, Oruetxebarria I, Raap AK, Verrijzer CP. 2005. Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev 19: 665670.
  • Wang GG, Allis CD, Chi P. 2007. Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. Trends Mol Med 13: 373380.
  • Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL, Crabtree GR. 1996a. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 15: 53705382.
  • Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR. 1996b. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 10: 21172130.
  • Wang X, Dong L, Xie J, Tong T, Zhan Q. 2009. Stable knockdown of Aurora-A by vector-based RNA interference in human esophageal squamous cell carcinoma cell line inhibits tumor cell proliferation, invasion and enhances apoptosis. Cancer Biol Ther 8: 18521859.
  • Wen X, Casey Klockow L, Nekorchuk M, Sharifi HJ, de Noronha CM. 2012. The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover. PLoS One 7: e30939.
  • Wilson BG, Roberts CW. 2011. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481492.
  • Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH, Roberts CW. 2010. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18: 316328.
  • Wu DY, Kalpana GV, Goff SP, Schubach WH. 1996. Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol 70: 60206028.
  • Wu DY, Krumm A, Schubach WH. 2000. Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol 74: 88938903.
  • Wu DY, Tkachuck DC, Roberson RS, Schubach WH. 2002. The human SNF5/INI1 protein facilitates the function of the growth arrest and DNA damage-inducible protein (GADD34) and modulates GADD34-bound protein phosphatase-1 activity. J Biol Chem 277: 2770627715.
  • Wurzenberger C, Gerlich DW. 2011. Phosphatases: Providing safe passage through mitotic exit. Nat Rev Mol Cell Biol 12: 469482.
  • Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR. 2005. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25: 23842394.
  • Yamauchi Y, Abe K, Mantani A, Hitoshi Y, Suzuki M, Osuzu F, Kuratani S, Yamamura K. 1999. A novel transgenic technique that allows specific marking of the neural crest cell lineage in mice. Dev Biol 212: 191203.
  • Yan A, Wang L, Xu S, Xu J. 2011. Aurora-A kinase inhibitor scaffolds and binding modes. Drug Discov Today 16: 260269.
  • Yoo AS, Crabtree GR. 2009. ATP-dependent chromatin remodeling in neural development. Curr Opin Neurobiol 19: 120126.
  • Young DW, Pratap J, Javed A, Weiner B, Ohkawa Y, van Wijnen A, Montecino M, Stein GS, Stein JL, Imbalzano AN, Lian JB. 2005. SWI/SNF chromatin remodeling complex is obligatory for BMP2-induced, Runx2-dependent skeletal gene expression that controls osteoblast differentiation. J Cell Biochem 94: 720730.
  • Yung E, Sorin M, Pal A, Craig E, Morozov A, Delattre O, Kappes J, Ott D, Kalpana GV. 2001. Inhibition of HIV-1 virion production by a transdominant mutant of Integrase interactor 1. Nat Med 7: 920926.
  • Yung E, Sorin M, Wang EJ, Perumal S, Ott D, Kalpana GV. 2004. Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance. J Virol 78: 22222231.
  • Zhang W, Wang J, Liu SJ, Hua W, Xin XY. 2009. Correlation between Aurora-A expression and the prognosis of cervical carcinoma patients. Acta Obstet Gynecol Scand 88: 521527.
  • Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV. 2002. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 22: 59755988.